Oxford BioMedica plc (OXB.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 04:35PM BST
| Previous close | 348.50 |
| Open | 342.38 |
| Bid | 362.50 x 0 |
| Ask | 364.50 x 0 |
| Day's range | 342.00 - 368.00 |
| 52-week range | 164.29 - 460.00 |
| Volume | |
| Avg. volume | 210,204 |
| Market cap | 387.519M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.63 |
| Earnings date | 18 Sept 2024 - 23 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 448.88 |
Globe NewswireOxford Biomedica announces CFO transition
Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK – 17 July 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Lucinda (Lucy) Crabtree Ph.D. as Chief Financial Officer (CFO) and Board member. Simultaneously, the Company announces that Stuart Paynter will step down as CFO and from the Board after
Simply Wall St.Oxford Biomedica plc (LON:OXB) is favoured by institutional owners who hold 53% of the company
Key Insights Significantly high institutional ownership implies Oxford Biomedica's stock price is sensitive to their...
- Simply Wall St.
Oxford Biomedica (LON:OXB) investors are sitting on a loss of 71% if they invested three years ago
Oxford Biomedica plc ( LON:OXB ) shareholders will doubtless be very grateful to see the share price up 89% in the last...
© 2024 Yahoo. All rights reserved.